This article has been updated to include comments from an FGT spokesman.
NEW YORK, May 25 (GenomeWeb News) - First Genetic Trust said today that it will apply its enTrust genetic banking platform in a research collaboration with GlaxoSmithKline to study the relationship between genetic variations and certain adverse drug reactions.
The companies entered a similar collaboration in October 2001. A company spokesman said that the current agreement marks an entirely new study, rather than an extension of the previous one. The initial study was focused more on developing the platform, he said, "and now we're using the platform to do another study."
FGT was unable to provide further details on the new study.
FGT said that GSK will use enTrust to collect, store, and manage patient enrollment, informed consent, and clinical data to support the project.
The system will also be used to re-contact patients online for additional consent for new research or phenotypic information, FGT said.